BIIB Biogen

Q3 2025 10-Q

Filed: Oct 30, 2025Period ending Sep 30, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Biogen (BIIB) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $2.535B for Q3 2025, up $68.9M (2.8%) YoY from $2.466B in Q3 2024
• Operating margin approx. 21.7% in Q3 2025 ($557.3M income before tax on $2.535B revenue) vs 18.3% in Q3 2024 ($451.0M on $2.466B)

+5 more insights

Risk Factors

• New risk: Generic TECFIDERA competition started in North America, Brazil, Europe triggering revenue decline and ongoing patent litigation in Europe through 2028
• Most updated risk: Impact of Inflation Reduction Act (IRA) Medicare Part D redesign expected to reduce 2025 revenue by $50-100M, mainly on SKYCLARYS and MS portfolio

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2.5B

▲ +2.8% YoY▼ -4.2% QoQ

Net Income

$467M

▲ +20.1% YoY▼ -26.5% QoQ

Net Margin

18.4%

▲ +265bp YoY▼ -559bp QoQ

Source: XBRL data from Biogen Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Biogen

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.